Oxford Biomedica Solutions
Evan DaSilva is a Scientist I currently at Oxford Biomedica (US) LLC since January 2023, following a role as Sr. Research Associate II in Analytical Development at Oxford Biomedica Solutions from March 2022 to February 2023. Prior experience includes positions at Homology Medicines, Inc., where Evan held various roles in Analytical Development from October 2019 to March 2022, and a Research Assistant role at Geisel School of Medicine at Dartmouth, focusing on cholera vaccine development between April 2017 and June 2019. Academic qualifications include a Master’s Degree in Genetics from the University of New Hampshire and a Bachelor of Arts in Biology from Hiram College, complemented by roles in teaching and research during graduate studies.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.